Biotechnology · Healthcare
CFO
Equibles does not estimate personal net worth.
Get an email with a short summary when Atea Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AVIR alertsAndrea Corcoran is recorded as CFO at Atea Pharmaceuticals, Inc. (AVIR). The newest filing on record that lists Andrea Corcoran as CFO at Atea Pharmaceuticals, Inc. (AVIR) is dated April 27, 2026. The proxy statement of Atea Pharmaceuticals, Inc. reports total compensation of $1,690,428 for Andrea Corcoran in fiscal 2025, including a base salary of $549,530. Disclosed compensation is on record for 7 fiscal years. Andrea Corcoran has spoken on 21 earnings calls across 1 company, most recently for Atea Pharmaceuticals, Inc. on November 9, 2026. Atea Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atea Pharmaceuticals, Inc. includes Jean-Pierre Sommadossi (CEO and Board Member), Wayne Foster (Chief Accounting Officer), Arthur Kirsch (Board Member) and 7 others.
“As Jonay mentioned in her introductory remarks, earlier today, we issued a press release containing our financial results for the third quarter of 2026. The Statement of Operations and Balance Sheet are on Slides 28 and 29.”
“As Jornay mentioned in her introductory remarks, earlier today we issued a press release containing our financial results for the first quarter of 2026. The Statement of Operations and Balance Sheet are on Slides 26 and 27.”
“As Jornay mentioned in her introductory remarks, earlier today we issued a press release containing our financial results for the fourth quarter and full year 2025.”
“As Jonay mentioned in her introductory remarks, earlier today we issued a press release containing our financial results for the third quarter of 2025. The statement of operations and balance sheet can be found on slides 24 and 25.”
“As Jonea mentioned, earlier today we issued a press release containing our financial results for the second quarter of 2025. The Statement of Operations and Balance Sheet are on Slides 23 and 24.”
Start not stated–present
Last confirmed April 27, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Financial Officer, Executive Vice President, Legal | $549,530 | $1,690,428 |
| 2024 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Financial Officer, Executive Vice President, Legal | $533,524 | $1,931,832 |
| 2023 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Financial Officer, Executive Vice President, Legal | $517,984 | $1,961,524 |
| 2022 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Financial Officer, Executive Vice President, Legal | $493,319 | $1,959,897 |
| 2021 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Financial Officer, Executive Vice President, Legal | $478,950 | $8,357,169 |
| 2020 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Financial Officer, Executive Vice President, Legal | $465,000 | $1,488,000 |
| 2019 | Atea Pharmaceuticals, Inc. (AVIR) | Chief Financial Officer, Executive Vice President, Legal | $290,000 | $440,324 |